Global Cybersecurity Exposure Assessment Across Leading Pharmaceutical Companies

Case Study

Client Situation

A consortium of globally recognized pharmaceutical companies sought to better understand their cybersecurity exposure in an increasingly complex threat environment. These organizations manage vast volumes of sensitive medical data, intellectual property, and critical research pipelines, making them prime targets for sophisticated cyberattacks.

While individual companies had internal security measures in place, there was limited visibility into industry-wide vulnerabilities, particularly across interconnected systems, third-party relationships, and employee-level exposure. Leadership recognized the need for an objective, data-driven assessment that could highlight systemic risks and inform both internal improvements and broader industry awareness.

Strategic Challenge

The pharmaceutical sector presents a uniquely high-risk cybersecurity profile due to:

  • The value of proprietary research, drug development data, and clinical trial results

  • The sensitivity of patient medical records and personally identifiable information (PII)

  • Complex global supply chains with multiple third-party access points

  • Large, distributed workforces with varying levels of security awareness

The challenge was to conduct a comprehensive, cross-company assessment that could:

  • Identify real-world vulnerabilities across multiple organizations

  • Quantify the operational impact of breaches

  • Maintain strict anonymity and confidentiality

  • Deliver actionable insights without exposing individual companies

Our Approach

We designed and executed a global, anonymized cybersecurity market study, combining technical analysis, exposure mapping, and risk quantification.

1. Multi-Dimensional Exposure Analysis

We assessed cybersecurity exposure across several critical dimensions:

  • Medical and patient data security

  • Internal systems and operational processes

  • Employee credential exposure and access vulnerabilities

  • Intellectual property protection

  • Third-party and supply chain risk

This approach provided a holistic view of how vulnerabilities could propagate across systems and organizations.

2. Identification of Active Breaches and Data Exposure

Our analysis revealed that multiple companies had already experienced significant breaches and data leaks, often without full awareness of the extent of exposure.

Findings included:

  • Compromised employee credentials circulating in underground channels

  • Sensitive corporate and operational data accessible via unsecured endpoints

  • Exposure of internal documents, contracts, and strategic plans

  • Availability of patient-related data and personally identifiable information

In several cases, information related to senior executives and their families—including personal details and sensitive records—was identified in dark web environments, significantly increasing the risk of targeted attacks, extortion, and social engineering.

3. Vulnerability Pathway Analysis

We identified specific entry points through which attackers gained access to corporate networks.

In one notable instance, attackers were able to access an entire corporate network through an unsecured network printer, demonstrating how seemingly minor vulnerabilities can escalate into full-system compromise.

These findings highlighted the importance of securing not only core systems, but also peripheral devices and overlooked infrastructure components.

4. Quantification of Technical Remediation Costs

To provide a practical perspective on risk, we calculated the technical remediation effort required to address identified vulnerabilities.

This included estimating:

  • Time required to patch compromised servers

  • Restoration of secure configurations (e.g., SSL and encryption protocols)

  • Revocation and reissuance of compromised credentials

  • System-wide access control remediation

Importantly, these estimates excluded litigation, regulatory penalties, and reputational damage, focusing solely on the operational burden. Even within this limited scope, the required remediation effort represented significant time and resource investment for affected organizations.

5. Industry-Level Advisory and Recommendations

Based on the findings, we developed a set of strategic and operational recommendations aimed at both individual companies and the broader pharmaceutical sector.

Key areas of focus included:

  • Strengthening credential management and monitoring systems

  • Securing endpoint devices and non-traditional access points

  • Enhancing third-party and supply chain risk management

  • Implementing continuous threat intelligence monitoring

  • Improving executive-level security and personal data protection

6. Anonymized Industry Dissemination

To maximize impact while protecting confidentiality, the study was conducted and presented in a fully anonymized format.

We shared the findings at a leading international third-party risk conference, enabling industry stakeholders to:

  • Understand systemic vulnerabilities

  • Benchmark their own security posture

  • Take proactive measures to mitigate risk

This approach ensured that the entire industry could benefit from the insights without exposing individual organizations to additional risk.

The Outcome

The study delivered a comprehensive and actionable view of cybersecurity risk across the pharmaceutical sector.

Key outcomes included:

  • Identification of widespread vulnerabilities across leading organizations

  • Increased awareness of real-world breach scenarios and exposure pathways

  • Quantification of operational remediation costs

  • Delivery of actionable recommendations for improving cybersecurity posture

  • Industry-wide dissemination of insights through a major conference platform

Strategic Impact

The project elevated cybersecurity from a technical concern to a strategic priority at the executive level within participating organizations.

By highlighting both the depth of exposure and the tangible cost of remediation, the study enabled companies to:

  • Prioritize security investments more effectively

  • Strengthen internal processes and controls

  • Improve resilience against future attacks

At an industry level, the anonymized approach fostered collective awareness and collaboration, helping to raise the overall security standard across the pharmaceutical ecosystem.

Key Insight

In highly interconnected industries such as pharmaceuticals, cybersecurity risk is not isolated—it is systemic. By combining deep technical analysis with industry-wide perspective and careful handling of sensitive information, organizations can move beyond reactive measures and build a more resilient, proactive security posture that protects both innovation and patient trust.